Clinical trials: Myelodysplastic Syndrome/Neoplasm
Tumor Lysis Syndrome, Cancer
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
This is a randomized, multi-center, open-label, parallel group study with three arms: Rasburicase alone Rasburicase followed by Allopurinol Allopurinol alone The primary objective is to compare the adequacy of control of plasma…
- Conditions
- Tumor Lysis Syndrome, Cancer, Hyperuricemia
- Trial name
- NCT00230178
- Testing
- Rasburicase (SR29142), Allopurinol
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Sanofi
Leukemia, Acute Disease
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
This study will evaluate the overall remission rate of treatment with vosaroxin (formerly voreloxin) Injection in patients at least 60 years of age with previously untreated AML
- Conditions
- Leukemia, Acute Disease, Acute Myeloid Leukemia, Nonlymphocytic Leukemia
- Trial name
- NCT00607997
- Testing
- vosaroxin
- Where
- 20 sites in United States
- Volunteers
- 113 people
- Sponsor
- Sunesis Pharmaceuticals
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to determine the activity of tamibarotene in participants with relapsed/refractory (R/R) AML (administered as a monotherapy or in combination with azacitidine), R/R higher-risk MDS (HR-MDS)…
- Trial name
- NCT02807558
- Testing
- Tamibarotene, Azacitidine, Daratumumab
- Where
- 26 sites in United States, France
- Volunteers
- 155 people
- Sponsor
- Syros Pharmaceuticals
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
The purpose of this study is to confirm the safety and tolerability of oral panobinostat (PAN) in combination with a fixed dose of 5-Azacitidine (5-Aza) in adult Japanese patients with Myelodysplastic Syndromes (MDS), Chronic…
- Conditions
- Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML)
- Trial name
- NCT01613976
- Testing
- Panobinostat
- Where
- 6 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Anemia
Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)
The purpose of this study is to evaluate the effects of luspatercept (MK-6143, formerly called ACE-536) on anemia in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS).
- Trial name
- NCT01749514
- Testing
- Luspatercept
- Where
- Germany
- Volunteers
- 116 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Myelodysplastic Syndrome (MDS)
Darbepoetin Alfa MDS Companion Protocol
The primary objective of the study was to provide required access of investigational product (darbepoetin alfa) beyond the end of the active treatment period (EOATP) of the darbepoetin alfa MDS 20090160 (NCT01362140) study for…
- Trial name
- NCT02175277
- Testing
- Darbepoetin Alfa
- Where
- 4 sites in Belgium
- Volunteers
- 9 people
- Sponsor
- Amgen
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS)
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This study is a phase I/II study of TJ011133 as Monotherapy and in Combination with Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).
- Trial name
- NCT04202003
- Testing
- TJ011133
- Where
- 26 sites in China
- Volunteers
- 105 people
- Sponsor
- TJ Biopharma Co., Ltd.
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
The purpose of this study is to determine the safety, pharmacokinetics and maximum tolerated dose of ABT-348 as monotherapy and when given in combination with azacitidine.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, B-cell Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT01110473
- Testing
- ABT-348, ABT-348 and azacitidine
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Myelodysplastic Syndrome
Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome
<Part I - Phase I trial> The phase I clinical trial is to identify the MTD (Maximum Tolerated Dose) and DLT (Dose Limiting Toxicity) of CG200745 PPA.
- Trial name
- NCT02737462
- Testing
- CG200745 PPA
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- CrystalGenomics, Inc.
Myelodysplastic Syndrome
Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
This study will explore the efficacy and safety of a regimen of ON 01910.Na as a 48-hour continuous intravenous infusion once a week for 3 weeks of a 4-week cycle in MDS patients with Trisomy 8 or classified as Intermediate-1, -2…
- Trial name
- NCT00906334
- Testing
- ON 01910.Na
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Traws Pharma, Inc.
Myelodysplastic Syndrome
MORE - Monitoring Revlimid - Collecting of Patient Information From Myelodysplastic Syndrome (MDS) Italian National Registry
The purpose of this study is to collect clinical and laboratory data for patients affected by intermediate 1 and low risk Myelodysplastic Syndrome (MDS) associated by deletion 5q who were prescribed Revlimid from 31October 2008…
- Trial name
- MORE (NCT01347944)
- Testing
- lenalidomide
- Where
- 45 sites in Italy
- Volunteers
- 149 people
- Sponsor
- Celgene
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Multicenter PK study of ASTX727 versus IV decitabine. Adult participants who were candidates to receive IV decitabine were randomized 1:1 to receive the ASTX727 tablet Daily×5 in Cycle 1 followed by IV decitabine 20 mg/m^2…
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT03306264
- Testing
- ASTX727, Dacogen
- Where
- 84 sites in United States, Austria and 8 more
- Volunteers
- 227 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Myelodysplastic Syndrome, Myelofibrosis
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
The purpose of this study is to assess the bioequivalence of subcutaneous Vidaza® and subcutaneous Luitpold Azacitidine pharmacokinetics and to assess the comparative safety of subcutaneous Vidaza® versus subcutaneous Luitpold…
- Conditions
- Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT01290302
- Testing
- Luitpold Azacitidine, Vidaza®
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- American Regent, Inc.
Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic…
- Conditions
- Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
- Trial name
- MOMENTUM (NCT07155226)
- Testing
- AZD3632, Posaconazole
- Where
- 30 sites in United States, Australia and 7 more
- Volunteers
- 85 people
- Sponsor
- AstraZeneca
Myelodysplastic Syndrome (MDS)
Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)
This is a randomized, open label, multicenter, Phase 2 study comparing two dose schedules of Telintra in patients with Low or Intermediate-1 risk MDS.
- Trial name
- NCT00700206
- Testing
- Ezatiostat Hydrochloride
- Where
- 36 sites in United States
- Volunteers
- 86 people
- Sponsor
- Telik
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving
The purpose of this study is to determine the safe dose of EPZ-5676, to evaluate the safety of EPZ-5676 in patients with advanced hematologic malignancies, and to conduct a preliminary assessment of the anti-leukemia activity of…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
- Trial name
- NCT01684150
- Testing
- EPZ-5676
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 51 people
- Sponsor
- Epizyme, Inc.
Leukemia, Acute Myeloid, Myelodysplastic Syndrome
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)
The primary objective of this study is to evaluate the safety, tolerability, and efficacy of temozolomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) participants who are not candidates for standard…
- Trial name
- TALL (NCT00687323)
- Testing
- temozolomide
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced myeloid malignancies. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and spread…
- Trial name
- NCT01606579
- Testing
- PRI-724
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Prism Pharma Co., Ltd.
Myelodysplastic Syndrome
Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)
The purpose of this study is to investigate tolerability when SyB L-1101 is administered intravenously in patients with recurrent/relapsed or refractory myelodysplastic syndrome, to determine the dose-limiting toxicity and…
- Trial name
- NCT01700335
- Testing
- SyB L-1101
- Where
- 3 sites in Japan
- Volunteers
- 9 people
- Sponsor
- SymBio Pharmaceuticals
Myelodysplastic Syndrome
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
The purpose of this study is to evaluate the efficacy of siltuximab, demonstrated by a reduction in red blood cell (RBC), transfusions to treat the anemia of Myelodysplastic Syndrome (MDS).
- Trial name
- NCT01513317
- Testing
- Siltuximab, Best supportive care (BSC)
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 76 people
- Sponsor
- Janssen Research & Development, LLC